Sartorius: A connected ecosystem for innovation success
Sartorius leverages ITONICS to streamline global innovation, enhance collaboration, and deliver future-driven technology insights in the life sciences market.

71 trends, from discovery and clinical development to pricing and patient engagement, each rated by potential impact and time to impact. Strategy and R&D teams in pharma track them in ITONICS and link every trend to the projects it affects.

Patent expiries put more than $200 billion of branded revenue at risk before 2030, and drugmakers have to refill their pipelines while the rules change in Washington, Brussels and Beijing at once. Four shifts set the pharma agenda for 2027 and beyond.
Price pressure hits both sides of the Atlantic. All 17 large drugmakers in the US pricing deals promised launch prices no higher than in other developed countries, Medicare negotiates prices for 15 more drugs from January 2027, and the EU pharma package cuts baseline data protection to eight years.
China turns from fast follower into a source of new medicines. Chinese biotechs licensed out assets worth about $110 billion in the first half of 2026, and Chinese partners account for 38% of big pharma's licensing deals.
Factories follow trade policy. The US charges tariffs of up to 100% on imported patented medicines since 29 September 2026, and branded drugmakers have announced roughly $500 billion in US investment.
More medicines work for months or years after a single dose. Twice-yearly injections prevent HIV, Lilly's base editor VERVE-102 cut LDL cholesterol by up to 62% after one infusion, and big pharma bought companies that make CAR-T cells inside the patient's body.
The ITONICS pharma radar below maps all 71 trends across six segments of the pharma value chain, from discovery to the patient.
The radar holds 71 trends that move at very different speeds. Some reshape budgets within two years, some hinge on a trial result or a law with a known date, and a few take most of the next decade.
Act on now. Four very-high-impact trends land within two years: China as big pharma's largest external source of new molecules, US tariffs that make local production a condition of market access, US pressure on European prices and the collapse in obesity drug prices.
Dates to watch. The first BIOSECURE list is due by December 2026, Medicare's negotiated prices for 15 more drugs start in January 2027, PBM delinking in Medicare Part D follows in January 2028, and EU joint clinical assessments extend to orphan medicines in 2028.
Against the consensus. Obesity drugs turn into a volume business, quantum computing stays a research bet for drug discovery, and gene therapy's commercial model breaks before its science does.
Quiet costs. EU wastewater charges, PFAS restrictions, new inhaler propellants and NHS supply chain carbon reporting add cost and supply risk.
Long bets. Eighteen trends sit six to ten years out, from in vivo CAR-T and one-time gene editing to brain shuttles and genome sequencing at birth.
Big pharma now buys a large share of its early pipeline from outside, with Chinese partners behind 38% of large pharma licensing deals, and AI moves deeper into the lab. The eleven discovery trends also cover venture funding, AI-run labs and rejuvenation therapies. Three discovery trends stand out:
Summary: Western drugmakers license a large share of their new clinical assets from Chinese biotechs, at rising prices. Chinese developers lead in antibody-drug conjugates, bispecifics and obesity programmes, and pipeline strategy shifts from internal discovery toward sourcing with geopolitical risk priced in.
Current situation: Out-licensing deals from greater China reached a record $137.7 billion in total value in 2025, according to Pharmcube data cited by Reuters, and China's drug regulator reported about $110 billion for the first half of 2026. Average upfronts for China-sourced deals rose from $52 million in 2022 to $172 million in early 2026, and Chinese partners account for 38% of large pharma licensing deals.
Expected development: Licensing keeps rising as patent expiries force big pharma to refill late-decade pipelines. Deals adapt through split regional rights, NewCo vehicles and manufacturing outside China, and the first BIOSECURE designations decide whether the flow continues on current terms.
Challenges: Data from China-only trials may not satisfy FDA and EMA without Western patients, and national security scrutiny is rising in Washington. Rising upfronts compress returns, and crowded targets invite duplicated bets.
Time to impact: 0-2 years
Potential impact: Very high
STEEP segment: Economic
Signals to watch:

Summary: AI has compressed target discovery and molecule design, and AI-discovered molecules pass phase 1 at high rates. No AI-discovered drug has completed phase 3, and Insilico's rentosertib trial is the first large test of whether AI improves the odds where most drugs fail.
Current situation: A 2024 analysis in Drug Discovery Today found that AI-discovered molecules cleared phase 1 at rates of 80 to 90%, while phase 2 failure rates matched conventional drugs. In September 2026 Insilico dosed the first patient in GENESIS-IPF-3, a 320-patient phase 3 trial in idiopathic pulmonary fibrosis with initial results planned for December 2029. Isomorphic Labs raised a $2.1 billion Series B in May 2026.
Expected development: Until the first phase 3 readouts, AI platforms are valued on partnership deal flow and phase 1 to phase 2 transitions. A positive rentosertib result would raise the price of AI-originated assets, while a failure would reposition AI as a productivity tool for chemistry and trial design.
Challenges: Most phase 2 failures stem from target biology, and definitions of an AI-discovered drug vary. Late-stage trials cost as much for AI-designed molecules as for others.
Time to impact: 4-6 years
Potential impact: High
STEEP segment: Technological
Signals to watch:
Summary: Conventional antibodies barely cross the blood-brain barrier. Receptor-mediated shuttles such as Roche's Brainshuttle deliver far more antibody into the brain, and early Alzheimer's data show faster plaque clearance with less brain swelling.
Current situation: In Roche's phase Ib/IIa Brainshuttle AD study, 91% of patients treated with trontinemab became amyloid PET negative, with ARIA-E below 5%. Roche runs the phase III TRONTIER 1 and 2 trials in early symptomatic Alzheimer's disease and has designed PrevenTRON, a prevention trial in people at high risk, using its pTau217 blood test.
Expected development: TRONTIER readouts toward the end of the decade decide whether shuttled antibodies become standard in Alzheimer's disease. Success would carry shuttles into Parkinson's disease, ALS and neuro-oncology and make shuttle platforms prime licensing targets.
Challenges: Receptor-mediated transport can carry off-target risks, including effects on red blood cells. Prevention trials are long and costly, and infusion capacity and MRI monitoring already limit uptake of anti-amyloid therapies.
Time to impact: 6-8 years
Potential impact: High
STEEP segment: Technological
Signals to watch:
Some trials get shorter while others get longer: residual-disease endpoints, digital twins and first-in-human studies in China speed development, while prevention drugs need outcome trials with thousands of patients. Three clinical development trends stand out:
Summary: GLP-1-based drugs now carry outcome labels beyond weight loss, and next-generation agonists approach the weight loss of surgery. Competition moves to tolerability, muscle preservation and outcome data across organs, and payers face a class that touches cardiology, nephrology, hepatology and sleep medicine at once.
Current situation: Semaglutide is approved for cardiovascular risk reduction, kidney protection in type 2 diabetes and MASH, and tirzepatide for obstructive sleep apnoea. Lilly's triple agonist retatrutide produced 28.3% average weight loss at 80 weeks in TRIUMPH-1, and in July 2026 TRIUMPH-3 showed 22.6% in people with severe obesity and heart disease. Lilly plans to file retatrutide with the FDA in the first quarter of 2027.
Expected development: Outcome trials in heart failure, kidney and liver disease expand labels and payer acceptance through 2028. Differentiation shifts to tolerability, dosing, lean mass and maintenance after weight loss.
Challenges: Gastrointestinal side effects and discontinuation limit real-world persistence, and long-term safety of very large weight loss needs more data. Payers struggle to fund chronic use across so many indications.
Time to impact: 2-4 years
Potential impact: Very high
STEEP segment: Technological
Signals to watch:

Summary: In vivo CAR-T delivers genetic instructions directly into the body, which removes the need to extract, engineer and reinfuse each patient's T cells. Early myeloma data show responses without lymphodepleting chemotherapy, and success would turn cell therapy into an off-the-shelf product.
Current situation: AstraZeneca acquired EsoBiotec for $425 million upfront in March 2025, AbbVie acquired Capstan for up to $2.1 billion in June 2025, and Gilead's Kite acquired Interius for $350 million upfront. Phase I data for AstraZeneca's ESO-T01 in multiple myeloma, published in March 2026, showed responses without lymphodepletion, and a hyperacute inflammatory reaction in the first patient led to prophylactic steroids.
Expected development: Phase 1 and 2 data through 2028 show whether responses last and whether safety can be managed outside specialist centres. Successful programmes would undercut autologous CAR-T on cost and open lupus and other autoimmune diseases to a one-time immune reset.
Challenges: Unintended transduction of non-target cells is a safety concern regulators will scrutinise, and dose control is harder without ex vivo selection. Pricing a one-time, off-the-shelf therapy is unresolved.
Time to impact: 6-8 years
Potential impact: Very high
STEEP segment: Technological
Signals to watch:
Summary: In vivo editing of liver genes such as PCSK9 and ANGPTL3 has lowered LDL cholesterol by 50 to 60% for more than a year after a single infusion. If outcome trials and long-term safety hold, cardiovascular prevention could shift from daily pills to a one-time treatment.
Current situation: In May 2026 Lilly reported that its base editor VERVE-102 cut LDL cholesterol by up to 62% after one infusion in 35 patients, with effects lasting up to 18 months, and plans to start phase 2 by the end of 2026. CRISPR Therapeutics' CTX310 cut LDL cholesterol by 52.5% at one year at the top dose, and a liver safety event paused a phase 3 programme of Intellia's editing therapy for transthyretin amyloidosis.
Expected development: Phase 2 and 3 programmes into the early 2030s must show durable lipid lowering and then outcome benefit, starting with familial hypercholesterolaemia. Payers will weigh a one-time price against decades of statins, PCSK9 antibodies and siRNA injections.
Challenges: Permanent edits cannot be reversed if late side effects emerge, and off-target edits and delivery-related liver toxicity remain open questions. A one-time price for a common condition strains annual budgets.
Time to impact: 8-10 years
Potential impact: High
STEEP segment: Technological
Signals to watch:
Regulators in the US and Europe rewrite the rules at the same time, each in its own direction, while new routes open for AI-generated evidence, analytically approved biosimilars and single-patient gene editing. Three regulatory trends stand out:
Summary: Both major markets are cutting the period in which a new medicine earns its return undisturbed. The EU pharma package lowers baseline regulatory protection, and US Medicare negotiation reaches small molecules seven years after approval and biologics after eleven.
Current situation: The EU's provisional agreement of 11 December 2025 replaces the 8+2+1 formula with eight years of data protection plus one year of market protection, conditional extensions and a cap of 11 years, and formal adoption is pending. Medicare negotiated prices for the first ten drugs took effect in January 2026, 15 more including semaglutide follow in January 2027, and the 2028 cycle brings Part B drugs into negotiation.
Expected development: Products filed before the 24-month cut-off keep the old protection periods, so the full EU effect lands on launches toward the end of the decade. Companies design programmes around the extension criteria, and the US gap between small molecules and biologics tilts portfolios toward biologics.
Challenges: Protection now differs by market, modality and indication, which complicates launch sequencing and asset valuation. Industry keeps lobbying to close the US small-molecule gap.
Time to impact: 2-4 years
Potential impact: Very high
STEEP segment: Political
Signals to watch:

Summary: The FDA's drug centre lost close to a fifth of its staff, and many divisions run under acting leaders. Approval volumes held up, rejections rose and high-profile reversals unsettled sponsors, so regulatory risk shifts from timelines to consistency.
Current situation: The agency is seeking to hire about 2,200 people and had secured 600 by mid-2026. The FDA issued about 79 decisions in the first half of 2026 against 85 a year earlier, with both novel approvals and rejections rising, and the second rejection of Replimune's melanoma therapy RP1 drew strong criticism.
Expected development: Sponsors invest more in pre-submission alignment and written agreements to reduce decision risk. Rehiring and AI tools may restore throughput from 2027, and some companies seek first approvals elsewhere to hedge US uncertainty.
Challenges: Political leadership can override review-team recommendations, and inconsistency raises the cost of capital for small biotechs that depend on a single approval.
Time to impact: 0-2 years
Potential impact: High
STEEP segment: Political
Signals to watch:
Summary: The FDA has proposed a framework that lets individualised genome-editing and RNA therapies for ultra-rare diseases gain approval on a plausible mechanism and small patient numbers. Rare disease development shifts from one drug per trial to platforms that produce many variant-specific products.
Current situation: On 23 February 2026 the FDA issued draft guidance on the plausible-mechanism framework, with comments due by 27 April 2026. It builds on the Rare Disease Evidence Principles from September 2025 and a 2025 case in which Children's Hospital of Philadelphia and Penn designed a CRISPR therapy for a baby with a rare metabolic disorder, and it lets several variants of one gene sit in a single application.
Expected development: Platform developers seek approval for an editing system plus a process to create variant-specific products, with real-world evidence collected after approval. The first approvals under the framework could arrive before 2030.
Challenges: Small evidence packages leave questions about long-term safety and durability, and manufacturing across many variants is complex. Payers may refuse to cover therapies approved on mechanism.
Time to impact: 4-6 years
Potential impact: High
STEEP segment: Political
Signals to watch:
Where medicines are made has turned into a political decision: tariffs pull branded production into the US, generic injectables keep running short, and environmental rules add pressure from inhaler propellants to supplier carbon reporting. Three manufacturing and supply chain trends stand out:
Summary: The US taxes imported patented medicines and their ingredients at up to 100% unless companies produce locally or hold pricing deals. Branded drugmakers answered with roughly $500 billion in announced US investment, while generics and several specialty categories remain exempt for now.
Current situation: Proclamation 11020 of 2 April 2026 imposed Section 232 tariffs on patented pharmaceuticals, their active ingredients and key starting materials, applying from 31 July 2026 for 17 named large manufacturers and from 29 September 2026 for all other importers. Generics, biosimilars, orphan drugs, cell and gene therapies and antibody-drug conjugates are exempt, and UK-origin products are exempt until January 2029.
Expected development: Much of the announced capacity is due by 2030, which shifts branded API and fill-finish toward the US and leaves European and Asian sites to serve generics and ex-US markets. Patent status becomes a customs question, and generic tariffs deferred until 2028 extend the pressure.
Challenges: New biologics plants take years to build and validate, so tariffs bite before capacity exists. Tariff terms can change through litigation, bilateral deals or a new administration.
Time to impact: 0-2 years
Potential impact: Very high
STEEP segment: Political
Signals to watch:

Summary: US drug shortages are rising again, led by cheap sterile injectables whose margins cannot fund redundancy and quality systems. Tariff exemptions keep generic imports flowing and leave their economics unchanged, so shortages stay structural.
Current situation: ASHP counted 227 active US drug shortages in the second quarter of 2026, the third consecutive quarterly increase after a 2025 low and down from a record 323 in early 2024. Generic sterile injectables make up the core of active shortages, and a severe ifosfamide shortage led the second-quarter increase.
Expected development: Purchasers test reliability premiums and multi-supplier contracts, and the EU's Critical Medicines Act, agreed provisionally in May 2026, brings resilience criteria into public procurement. Shortages persist through 2028 because new sterile plants take years to build.
Challenges: Purchasing practices favour the lowest bid and sole awards, and a quality failure at a single plant can remove a large share of supply.
Time to impact: 0-2 years
Potential impact: High
STEEP segment: Economic
Signals to watch:
Summary: Extreme weather already causes drug shortages when one plant supplies a large share of a market. Nearly two-thirds of US drug production facilities sit in counties prone to climate-related disasters, and key Indian hubs face heat, flood and water stress.
Current situation: In September 2024 Hurricane Helene flooded Baxter's North Cove plant in North Carolina, which made about 60% of the IV fluid bags used in US hospitals, forcing rationing into 2025. A 2025 JAMA research letter found 62.8% of US pharmaceutical facilities in counties prone to climate-related disasters, and Lupin reports exposure at sites including Mumbai, Vadodara and Visakhapatnam.
Expected development: Through the 2030s, purchasers and regulators require climate risk assessments, dual sourcing and buffer stocks for critical medicines. Companies harden sites against floods and heat and spread production across climate zones.
Challenges: Redundant capacity raises costs for low-margin products, and site-level climate risk data is incomplete. Onshoring can move production into regions with their own climate exposure.
Time to impact: 6-8 years
Potential impact: High
STEEP segment: Ecological
Signals to watch:
Pricing carries the most immediate risk on the radar, with three of the eight very-high-impact trends here, and Medicare's PBM reform and EU joint clinical assessments change how net prices and launch evidence work. Three market access and pricing trends stand out:
Summary: Most-favoured-nation pricing ties US launch prices to those in other rich countries, so companies push for higher prices abroad or delay launches there. The UK raised its NICE threshold for the first time since 1999, and other European payers face a choice between paying more and waiting longer.
Current situation: Under the UK-US pharmaceutical deal of December 2025, the UK secured zero tariffs on drug exports to the US and raised NICE's threshold from £20,000 to £30,000 per QALY to £25,000 to £35,000 from April 2026. The UK committed to raise medicines spending toward 0.6% of GDP and to cut the VPAG rebate rate to 15% in 2026, and all 17 large drugmakers in the US deals committed to launch prices no higher than in other developed countries.
Expected development: Companies hold back launches in low-price European markets unless prices rise, which pressures Germany, France, Italy and Spain to revise pricing rules or accept slower access. Confidential rebates grow in importance.
Challenges: Higher prices strain European health budgets, and delayed launches provoke political backlash. US policy could change after 2028, leaving Europe with commitments that outlast the pressure.
Time to impact: 0-2 years
Potential impact: Very high
STEEP segment: Economic
Signals to watch:

Summary: The price of obesity treatment is falling on three fronts at once: semaglutide generics outside the US, US cash prices from $149 a month for pills and Medicare coverage at $245 a month. Volume grows while revenue per patient shrinks.
Current situation: Semaglutide patents expired in India on 20 March 2026, and Indian companies launched generics roughly 70% or more below Novo Nordisk's brands, with patents expiring in about ten countries in 2026. In the US, Lilly and Novo agreed Medicare prices of $245 a month with $50 copays through the Medicare GLP-1 Bridge from July 2026 to December 2027.
Expected development: Price competition spreads from India to Canada, Brazil, China and other markets through 2027, and branded US net prices fall toward Medicare levels. Revenue growth shifts to next-generation agonists and new indications.
Challenges: US semaglutide patents run to about 2032, so the price gap invites gray imports. Several states dropped Medicaid coverage for obesity drugs, and lower prices squeeze returns on manufacturing investment.
Time to impact: 0-2 years
Potential impact: Very high
STEEP segment: Economic
Signals to watch:
Summary: Medicines that lower a genetic risk factor before disease appears promise huge markets. In September 2026 the first Lp(a) outcomes trial lowered the biomarker and failed to reduce heart attacks and strokes, so payers will fund population-scale prevention only with hard outcome data.
Current situation: Novartis reported on 4 September 2026 that pelacarsen did not significantly reduce major adverse cardiovascular events in the 8,323-patient Lp(a)HORIZON trial. The 2026 ACC/AHA guideline recommends measuring Lp(a) in all adults at least once, Amgen's olpasiran trial lists completion for March 2028 and Lilly's lepodisiran trial for March 2029.
Expected development: The OCEAN(a) and ACCLAIM-Lp(a) readouts decide whether deeper Lp(a) lowering creates a prevention market, while universal testing builds a large identified population either way. Across prevention, sponsors need longer and costlier outcome trials.
Challenges: Primary prevention trials need very large populations and long follow-up, and treating millions of people without symptoms creates a budget impact payers resist.
Time to impact: 6-8 years
Potential impact: High
STEEP segment: Economic
Signals to watch:
Commercial models change faster than any other part of the value chain, with six of eleven trends landing within two years, and diagnosis moves earlier through blood tests and genome sequencing at birth. Three commercialization trends stand out:
Summary: Manufacturer cash-pay channels have moved from niche programmes to federally promoted infrastructure. TrumpRx, launched in February 2026, routes patients to company offers at most-favoured-nation prices, which gives manufacturers patient relationships and exposes net prices the rebate system used to hide.
Current situation: All 17 large drugmakers approached by the White House in July 2025 signed MFN deals, which the administration says cover about 86% of the branded US market. TrumpRx launched with around 40 products and listed more than 800 by August 2026, and in August ten pharmacy benefit managers committed to show TrumpRx cash prices in prescribers' real-time benefit tools.
Expected development: Direct channels extend from obesity and primary-care brands to specialty products with high out-of-pocket costs. PBM economics come under pressure as cash prices appear at the point of prescribing.
Challenges: Cash purchases may not count toward insurance deductibles, and Reuters found many TrumpRx prices above those paid in the UK. The deals are voluntary, so their durability depends on politics.
Time to impact: 0-2 years
Potential impact: High
STEEP segment: Economic
Signals to watch:

Summary: Clinical AI tools have become a first stop for many US doctors seeking treatment information, and some are funded by pharma advertising. How a drug appears in AI-generated answers starts to matter as much as rep visits or journal ads.
Current situation: OpenEvidence, a free AI search tool funded by pharmaceutical and device advertising, reported more than 757,000 verified US clinicians and was valued at $12 billion in early 2026. A March 2026 survey of 1,165 physicians in seven countries found 83% used ChatGPT at work and 36% OpenEvidence, and OpenAI launched ChatGPT for Clinicians in April 2026.
Expected development: Pharma shifts budget from detailing and journal ads to AI platforms, structured evidence and generative engine optimisation of medical information. Field forces shrink and concentrate on complex products where AI answers fall short.
Challenges: AI answers can be wrong or outdated, and advertising in clinical decision tools raises conflict-of-interest concerns. Companies have little control over how models summarise their evidence.
Time to impact: 0-2 years
Potential impact: High
STEEP segment: Social
Signals to watch:
Summary: Large studies in England and New York sequence newborns for hundreds of treatable genetic conditions, and most confirmed cases are disorders that standard screening misses. If health systems adopt genomic screening, rare disease companies gain earlier, larger and better-defined patient populations.
Current situation: New York's GUARDIAN study screened 4,000 newborns in its first analysis in JAMA, and 92% of the 120 confirmed cases were outside standard panels. England's Generation Study had recruited 52,000 of its planned 100,000 newborns by March 2026, ahead of schedule, and the NHS 10 year plan aims to make genomic sequencing for babies universal in England by 2035.
Expected development: Health systems decide in the early 2030s whether to add genome sequencing to routine newborn screening. Rare disease developers design trials and launch plans around pre-symptomatic cohorts.
Challenges: Variants of uncertain significance can cause anxiety and over-treatment, and consent and later use of genomes raise ethical questions. Health systems must fund confirmatory testing, follow-up and the therapies themselves.
Time to impact: 6-8 years
Potential impact: High
STEEP segment: Social
Signals to watch:
Download all 71 pharma trends with current situation, expected development, challenges and ratings for your next portfolio review or strategy workshop.
Download all 71 pharma trends 2027+
In ITONICS, R&D, strategy and business development teams rate the trends with their own experts and link each one to the programmes it affects.
Eight trends carry very high potential impact. Four hit within two years: China as big pharma's largest external source of new molecules, US tariffs that tie market access to US production, US pressure on European drug prices and the collapse in obesity drug prices. The other four follow later: shorter exclusivity in Europe and the US, a patent cliff worth more than $200 billion, incretin drugs as a multi-organ franchise and in vivo CAR-T.
Since 29 September 2026, Section 232 tariffs of up to 100% apply to imported patented medicines, their active ingredients and key starting materials, while generics, biosimilars, orphan drugs, cell and gene therapies and antibody-drug conjugates are exempt for now. Branded API and fill-finish move toward the US as new plants open toward 2030, and a product's tariff treatment changes once its patents expire.
AI already speeds up target discovery, molecule design and regulatory writing, and many doctors look up treatments in AI tools. Its clinical value is still open: the first phase 3 trial of an AI-discovered drug, Insilico's rentosertib, expects initial results around December 2029.
Eighteen of the 71 trends sit six to ten years out, led by in vivo CAR-T, one-time gene editing for cholesterol, digital twins in clinical trials, AI-run labs, brain shuttles and genome sequencing at birth. Decisions on these trends belong in today's discovery and early clinical portfolios.
They rate each trend against their own assets and link it to the programmes it affects, so a change in pricing, regulation or science shows up where budget decisions are made. Pharma teams do this in ITONICS and bring that view into portfolio and stage-gate reviews.
Big pharma sources a large share of its new clinical assets from outside, and Chinese partners alone account for 38% of its licensing deals, with average upfronts for China-sourced deals up from $52 million in 2022 to $172 million in early 2026. ITONICS gives scouting teams one place to track trends, technologies and startups, rate them with internal experts and connect each one to the projects it affects.
Sartorius leverages ITONICS to streamline global innovation, enhance collaboration, and deliver future-driven technology insights in the life sciences market.

Benedikt Heuer from WS Audiology unveils key innovation management strategies, foresight tools, and expansion plans that drive global success in the hearing aid industry.
